SI
FPRX

Sofinnova Investments’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Sofinnova Investments’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-315,344
Closed -$2.93M – 77
2018
Q4 		$2.93M Buy
+315,344
New +$3.75M 0.37% 48

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sofinnova Investments's FPRX Position: Q1 2019 in Review

Sofinnova Investments sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2019, closing a stake of 315,344 shares — an estimated $2.93M sold.

Sofinnova Investments first reported a position in FPRX in Q4 2018 and held it in 1 quarter. The position peaked at $2.93M in Q4 2018. 113 funds tracked by Wall St. Rank hold FPRX as of Q1 2019.

  • Sofinnova Investments reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
  • Sofinnova Investments sold 315,344 Five Prime Therapeutics, Inc. shares in Q1 2019, an estimated $2.93M.
  • Sofinnova Investments first reported a position in Five Prime Therapeutics, Inc. in Q4 2018 and held it in 1 quarter.
  • Sofinnova Investments's Five Prime Therapeutics, Inc. position peaked at $2.93M in Q4 2018.
  • 113 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2019.

Based on Sofinnova Investments's 13F filing for Q1 2019, filed 15 May 2019.